Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia
Ibrutinib, a first-generation Bruton tyrosine kinase inhibitor (BTKi) indicated for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), was found to have similar efficacy across the ALPINE (NCT03734016) and ELEVATE-RR (NCT02477696) trials …